Seagate to Participate in Upcoming Investor Event
Get Alerts STX Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.2%
Revenue Growth %: +42.2%
Join SI Premium – FREE
FREMONT, Calif.--(BUSINESS WIRE)-- Seagate Technology Holdings plc (NASDAQ: STX), a world leader in mass-data storage infrastructure solutions, today announced that management is scheduled to participate in the following investor event:
Event: |
Goldman Sachs Communacopia + Technology Conference |
|
Date: |
Tuesday, September 5, 2023 |
|
Time: |
Presentation – 10:10 AM PT / 1:10 PM ET |
A live webcast of this event can be accessed online at Seagate’s Investor Relations website at investors.seagate.com.
A replay of this webcast will be available for at least 30 days following the event.
About Seagate
Seagate Technology is the leading innovator of mass-capacity data storage solutions. We create breakthrough technology so you can confidently store your data and easily unlock its value. Founded over 45 years ago, Seagate has shipped over four billion terabytes of data capacity and offers a full portfolio of storage devices, systems, and services from edge to cloud. To learn more about how Seagate leads storage innovation, visit www.seagate.com and our blog, or follow us on Twitter, Facebook, LinkedIn, and YouTube.
© 2023 Seagate Technology LLC. All rights reserved. Seagate, Seagate Technology, and the Spiral logo are registered trademarks of Seagate Technology LLC in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230822299499/en/
Media Contact:
Gregory Belloni (415) 235-9092
[email protected]
Investor Relations Contact:
Shanye Hudson (510) 661-1600
[email protected]
Source: Seagate Technology Holdings plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox Advisors Downgrades Seagate Technology (STX) to Equalweight
- FROM STATESIDE TO SILVERSTONE: JIM BEAM® AND THE CADILLAC FORMULA 1® TEAM TOAST TO AMERICA'S 250TH AT THE BRITISH GRAND PRIX
- FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Goldman Sachs, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share